BRPI0814991A2 - Micro-rnas que controlam a expressão de miosina e identidade de miofibra. - Google Patents

Micro-rnas que controlam a expressão de miosina e identidade de miofibra.

Info

Publication number
BRPI0814991A2
BRPI0814991A2 BRPI0814991A BRPI0814991A2 BR PI0814991 A2 BRPI0814991 A2 BR PI0814991A2 BR PI0814991 A BRPI0814991 A BR PI0814991A BR PI0814991 A2 BRPI0814991 A2 BR PI0814991A2
Authority
BR
Brazil
Prior art keywords
microbes
myosin expression
myofiber
identity
control
Prior art date
Application number
Other languages
English (en)
Inventor
Eric Olson
Eva Van Rooij
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BRPI0814991A2 publication Critical patent/BRPI0814991A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0814991 2007-07-31 2008-07-31 Micro-rnas que controlam a expressão de miosina e identidade de miofibra. BRPI0814991A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95291107P 2007-07-31 2007-07-31
US98011307P 2007-10-15 2007-10-15
US98031407P 2007-10-16 2007-10-16
PCT/US2008/071837 WO2009018492A2 (en) 2007-07-31 2008-07-31 Micro-rnas that control myosin expression and myofiber identity

Publications (1)

Publication Number Publication Date
BRPI0814991A2 true BRPI0814991A2 (pt) 2015-03-31

Family

ID=40305287

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814991 BRPI0814991A2 (pt) 2007-07-31 2008-07-31 Micro-rnas que controlam a expressão de miosina e identidade de miofibra.

Country Status (11)

Country Link
US (2) US8481507B2 (pt)
EP (1) EP2187896B1 (pt)
JP (2) JP5654347B2 (pt)
KR (1) KR20100057022A (pt)
CN (1) CN101808649B (pt)
AU (1) AU2008283794B2 (pt)
BR (1) BRPI0814991A2 (pt)
CA (1) CA2694928A1 (pt)
MX (1) MX2010001216A (pt)
NZ (1) NZ583025A (pt)
WO (1) WO2009018492A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006310A (es) * 2006-12-14 2009-07-22 Novartis Ag Composiciones y metodos para tratar trastornos musculares y cardiovasculares.
RU2515926C2 (ru) * 2009-02-04 2014-05-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
CA2804791C (en) 2010-07-08 2019-07-30 Duke University Direct reprogramming of cells to cardiac myocyte fate
WO2012061810A1 (en) 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides
KR20140004646A (ko) 2010-12-15 2014-01-13 미라젠 세러퓨틱스 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
US8455518B2 (en) * 2010-12-28 2013-06-04 Avon Products, Inc. Method of treating skin with microRNA modulators
KR20140091688A (ko) * 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
KR101426530B1 (ko) * 2012-10-04 2014-08-05 한국과학기술연구원 형광 검출기를 포함한 모세관 전기영동법을 이용한 ｍｉＲＮＡ의 검출 방법
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
CA2903845C (en) * 2013-03-15 2022-08-23 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
CN105154445B (zh) * 2014-06-12 2018-07-27 中国科学院上海生命科学研究院 新的肌营养不良肌病的血清miRNA标志物
CA2957618A1 (en) * 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
JP6978774B2 (ja) * 2015-11-06 2021-12-08 国立大学法人 熊本大学 心不全の予防又は治療のための医薬組成物
JP6692638B2 (ja) * 2015-12-18 2020-05-13 花王株式会社 ＰＰＡＲδ活性化剤
CN106924757B (zh) * 2015-12-31 2020-07-24 中国科学院遗传与发育生物学研究所 miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用
EP3426781B1 (en) 2016-03-07 2024-06-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Micrornas and methods of their use
CN105695606B (zh) * 2016-04-07 2020-08-28 昆明理工大学 用于非治疗目的的肥厚型心肌病相关致病基因突变的筛查方法
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
US20230103731A1 (en) * 2020-03-02 2023-04-06 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
KR20230096756A (ko) * 2021-12-23 2023-06-30 사회복지법인 삼성생명공익재단 miR-499-5p 활성화제를 포함하는 뒤센 근이영양증 예방 또는 치료용 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414421A1 (en) 2000-07-31 2002-02-07 Gene Logic, Inc. Molecular toxicology modeling
EP2447370B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
AU2003219713A1 (en) 2002-02-04 2003-09-02 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
EP1723162A4 (en) 2004-02-13 2010-05-05 Univ Rockefeller ANTI-microRNA oligonucleotide molecules
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
WO2006013561A2 (en) 2004-08-02 2006-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for diagnosing and treating post traumatic stress disorder
JP2006101790A (ja) 2004-10-06 2006-04-20 Japan Health Science Foundation 高血圧症のリスクの評価方法
US20080269072A1 (en) 2004-10-21 2008-10-30 Hart Ronald P Rational Probe Optimization for Detection of MicroRNAs
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
CN101203611B (zh) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 控制基因表达的改良方法
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
WO2007035684A2 (en) 2005-09-16 2007-03-29 Primera Biosystems, Inc. Method for quantitative detection of short rna molecules
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
KR101485071B1 (ko) 2005-12-12 2015-01-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 마이크로 ｒｎａ를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 ｒｎａ 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트
WO2007073737A1 (en) 2005-12-29 2007-07-05 Exiqon A/S Detection of tissue origin of cancer
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
EP2007888A2 (en) * 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
US20090306181A1 (en) 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
EP2208798B1 (de) 2006-10-09 2013-08-07 Medizinische Hochschule Hannover MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
AU2007323469B2 (en) 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
MX2009006310A (es) * 2006-12-14 2009-07-22 Novartis Ag Composiciones y metodos para tratar trastornos musculares y cardiovasculares.
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
WO2008147837A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas
US20100292099A1 (en) 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
KR20100099158A (ko) 2007-11-09 2010-09-10 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
WO2009114681A2 (en) 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
EP2303292A4 (en) 2008-06-09 2013-01-02 New York Medical College COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods

Also Published As

Publication number Publication date
CA2694928A1 (en) 2009-02-05
AU2008283794A1 (en) 2009-02-05
JP5654347B2 (ja) 2015-01-14
EP2187896A2 (en) 2010-05-26
EP2187896B1 (en) 2016-01-13
AU2008283794B2 (en) 2014-03-20
JP2015013864A (ja) 2015-01-22
KR20100057022A (ko) 2010-05-28
US8481507B2 (en) 2013-07-09
US20100269183A1 (en) 2010-10-21
US20130245092A1 (en) 2013-09-19
WO2009018492A3 (en) 2010-01-21
US8962588B2 (en) 2015-02-24
EP2187896A4 (en) 2011-10-19
WO2009018492A2 (en) 2009-02-05
JP2010535246A (ja) 2010-11-18
CN101808649A (zh) 2010-08-18
NZ583025A (en) 2012-06-29
CN101808649B (zh) 2014-05-21
HK1143948A1 (en) 2011-01-21
MX2010001216A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
BRPI0814991A2 (pt) Micro-rnas que controlam a expressão de miosina e identidade de miofibra.
FR2929502B1 (fr) Implant nucleique.
BRPI0813527A2 (pt) Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
PT4397376T (pt) Combinação que compreende um inibidor de mek inhibitor e um inibidor de b-raf
BRPI0821445A2 (pt) Folha, processo de fabricação de uma folha, e, artigo
EP2197894A4 (en) DISSOLVING OLIGONUCLEOTIDES AND ITS USES
PL4223257T3 (pl) Niskoprofilowa przezcewnikowa zastawka serca
EP2158241A4 (en) ANCHORED POLYSILOXAN-MODIFIED POLYURETHANE COATINGS AND APPLICATIONS THEREOF
EP2271354A4 (en) REINFORCED TISSUE TRANSPLANT
BRPI0908995A2 (pt) polímeros acrílicos que possuem colocação controlada de grupos funcionais
BR112012002877A2 (pt) dilatador e conjunto.
DK2321361T3 (da) Anioniske vandige polyurethandispersioner
BRPI0912803A2 (pt) couro natural
BRPI0811543A2 (pt) Processo de geração de cumeno.
BRPI0811862A2 (pt) Membro de tensão amortecido ativamente.
BRPI0919095A2 (pt) etiqueta de rfid
BR112012000787A2 (pt) elemento de fixação auto-perfurante.
FR2949783B1 (fr) Polyurethanes associatifs a base de cardanol, epaississants associatifs correspondants et leurs utilisations.
FR2939972B1 (fr) Borne
BRPI0919681A2 (pt) processo para a fabricação de uma fibra ou folha, e, fibra ou folha
IT1392200B1 (it) Stabilizzatore vertebrale modulare.
BRPI0812254A2 (pt) Confirmação de identidade
EP2268289A4 (en) ANTI-INFECTIVES AND USES THEREOF
BRPI0916403A2 (pt) Matriz polimérica inseticida.
FI20085395A0 (fi) Ilmanvaihtokanava

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.